Anzeige
Meldung des Tages: 307 Meter Gold: Dieser Treffer könnte diese Goldaktie jetzt neu bewerten

PAVmed Aktie News

Aktie
WKN:  ISIN:  US70387R5028 US-Symbol:  PAVM
8,09 $
-0,56 $
-6,47%
6,7610 € 28.01.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

PAVmed News

21.01.26 - PR Newswire
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard® PR Newswire
30.12.25 - PR Newswire
PAVmed Announces Reverse Stock Split
PAVmed Announces Reverse Stock Split PR Newswire
09.12.25 - PR Newswire
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-​World Experience of Esophageal Precancer Detection PR Newswire
20.11.25 - PR Newswire
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-​Ranking Honoree PR Newswire
13.11.25 - PR Newswire
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire
13.11.25 - PR Newswire
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire
12.11.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire
30.10.25 - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 PR Newswire
29.10.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 PR Newswire
15.10.25 - PR Newswire
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit PR Newswire
07.10.25 - PR Newswire
PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement
PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement PR Newswire
25.09.25 - PR Newswire
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors PR Newswire
16.09.25 - PR Newswire
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs PR Newswire
11.09.25 - PR Newswire
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics Announces Closing of Public Offering of Common Stock PR Newswire
10.09.25 - PR Newswire
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock PR Newswire
09.09.25 - PR Newswire
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
Lucid Diagnostics Announces Proposed Public Offering of Common Stock PR Newswire
05.09.25 - PR Newswire
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 PR Newswire
27.08.25 - PR Newswire
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 PR Newswire
26.08.25 - PR Newswire
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology PR Newswire
14.08.25 - PR Newswire
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results PR Newswire

Newssuche

Videos

newspaper
27.01.26 +1,29%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »